Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical pharmacokinetics of methotrexate.

Literature DB >> 346283

Clinical pharmacokinetics of methotrexate.

D D Shen, D L Azarnoff.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 1978 PMID： 346283 DOI： 10.2165/00003088-197803010-00001

Source DB: PubMed Journal: Clin Pharmacokinet ISSN： 0312-5963 Impact factor: 6.447

× No keyword cloud information.

59 in total

1. METHOTREXATE DISPLACEMENT IN MAN.

Authors: D G JOHNS; J W HOLLINGSWORTH; A R CASHMORE; I H PLENDERLEITH; J R BERTINO
Journal: J Clin Invest Date: 1964-04 Impact factor: 14.808

2. Stoichiometric inhibition of mammalian dihydrofolate reductase by the gamma-glutamyl metabolite of methotrexiate, 4-amino-4-deoxy-N-10-methylpteroylglutamyl-gamma-glutamate.

Authors: S A Jacobs; R H Adamson; B A Chabner; C J Derr; D C Johns
Journal: Biochem Biophys Res Commun Date: 1975-04-07 Impact factor: 3.575

3. Polygammaglutamyl metabolites of methotrexate.

Authors: C M Baugh; C L Krumdieck; M G Nair
Journal: Biochem Biophys Res Commun Date: 1973-05-01 Impact factor: 3.575

4. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors: E S Henderson; R H Adamson; V T Oliverio
Journal: Cancer Res Date: 1965-08 Impact factor: 12.701

5. Pharmacokinetics of methotrexate.

Authors: D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal: Clin Pharmacol Ther Date: 1973 Jul-Aug Impact factor: 6.875

6. The effect of organic acids on renal clearance of methotrexate in man.

Authors: D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal: Clin Pharmacol Ther Date: 1969 Nov-Dec Impact factor: 6.875

7. The characteristics of the membrane transport of amethopterin and the naturally occurring folates.

Authors: I D Goldman
Journal: Ann N Y Acad Sci Date: 1971-11-30 Impact factor: 5.691

8. Letter: Purity of methotrexate.

Authors: W P Tong; J Resenberg; D B Ludlum
Journal: Lancet Date: 1975-10-11 Impact factor: 79.321

9. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion.

Authors: H M Pinedo; D S Zaharko; J Bull; B A Chabner
Journal: Cancer Res Date: 1977-02 Impact factor: 12.701

10. Tissue-specific synthesis of methotrexate polyglutamates in the rat.

Authors: V M Whitehead; M M Perrault; S Stelcner
Journal: Cancer Res Date: 1975-11 Impact factor: 12.701

48 in total

1. Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma.

Authors: D J Grimes; M R Bowles; J A Buttsworth; D B Thomson; P J Ravenscroft; P F Nixon; R F Whiting; S M Pond
Journal: Drug Saf Date: 1990 Nov-Dec Impact factor: 5.606

2. Variability of oral bioavailability for low dose methotrexate in rats.

Authors: T Kuroda; K Namba; T Torimaru; S Yamamoto; M Akahori
Journal: Eur J Drug Metab Pharmacokinet Date: 2001 Oct-Dec Impact factor: 2.441

Review 3. Guide to drug dosage in renal failure.

Authors: W M Bennett
Journal: Clin Pharmacokinet Date: 1988-11 Impact factor: 6.447

Review 4. Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors: F M Balis
Journal: Clin Pharmacokinet Date: 1986 May-Jun Impact factor: 6.447

5. Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors: Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal: Br J Clin Pharmacol Date: 2014-08 Impact factor: 4.335